IL-1β in atherosclerotic vascular calcification: From bench to bedside

Atherosclerotic vascular calcification contributes to increased risk of death in patients with cardiovascular diseases. Assessing the type and severity of inflammation is crucial in the treatment of numerous cardiovascular conditions. IL-1 beta, a potent proinflammatory cytokine, plays diverse roles in the pathogenesis of atherosclerotic vascular calcification. Several large-scale, population cohort trials have shown that the incidence of cardiovascular events is clinically reduced by the administration of anti-IL-1 beta therapy. Anti-IL-1 beta therapy might reduce the incidence of cardiovascular events by affecting atherosclerotic vascular calcification, but the mechanism underlying this effect remains unclear. In this review, we summarize current knowledge on the role of IL-1 beta in atherosclerotic vascular calcification, and describe the latest results reported in clinical trials evaluating anti-IL-1 beta therapies for the treatment of cardiovascular diseases. This review will aid in improving current understanding of the pathophysiological roles of IL-1 beta and mechanisms underlying its activity.

Automated summary

Atherosclerotic vascular calcification is associated with increased risk of death in patients with cardiovascular diseases. IL-1 beta plays diverse roles in the pathogenesis of this condition, and anti-IL-1 beta therapy has shown to reduce the incidence of cardiovascular events, though the underlying mechanism remains unclear. This review summarizes current knowledge and clinical trial results on the role of IL-1 beta in atherosclerotic vascular calcification.